The latest corona virus attack is reminiscent of the deadly H1N1 influenza (Spanish Flu) that swept past the globe a hundred years ago, affecting 500 million people (almost one third of the global population at that time). In the distant past, when man had not been in a position to tame the furies, virus outbreaks in the form of smallpox and plague, used to decimate world population synergising the fratricidal wars. When our race checkmated poxes and Black Death, new virus strains, such as COVID 19 and HIV, make their debut to fill in the vacuum.
The latest version of corona virus has affected largely the northern hemisphere, especially the tropical and subtropical belt. The notorious Russian winter seems to barricade the country against the virus, when the Spring season comes increased UV radiations are likely to make the off-host survival rate much less for the virus in the affected regions.
The latest pandemic has its epicentre in Wuhan, a logistic and industrial nerve centre on the Yangtze and the Han. The panic triggered by the epidemic has come down heavily on the Chinese industry, casting a long shadow of despondency across the globe as a domino effect. The economic and human cost of the pandemic and the looming threat of similar editions of virus outbreaks have driven the research organizations to take on the challenge.It is remarkable that within a short span of time more than seven thousand patented publications have hit the market. This implies that the world is becoming more sensitive to the nuisance value of the viruses and the pharmaceutical and economic dimensions of the same. Figure 1 shows the geographical distribution of the patent publications related to Coronavirus.
At present, there are ten major players that are working on finding a solution for Coronaviruses, most of which are US-based with Pfizer and the US National Institute of Health taking the lead. In 2009 -10 period, when virus outbreaks became an alarming reality in the US, there was a surge in publications in the area.The publishing and technology trends in the competitive world of pharmacology make interesting reading in the present context, as shown in Figure 2. Most of the researches are directed towards medicinal preparations containing antigens or antibodies (3,057), followed by antibiotics, antiseptics, chemotherapeutics (2,551). Other strategies include medicinal preparations containing organic active ingredients, mutation or genetic engineering, Peptides having more than 20 amino acids, Gastrins, Somatostatins and Melanotropins, Medicinal preparations containing peptides and Viruses, Bacteriophages. There are various other approaches too, which did not claim much attention.
Virology and therapeutics pertaining to virus infections will remain to be a challenging arena given the propensity of the viruses to undergo mutation to trigger new epidemics. The characteristics of virus infection is that it defies antibiotics and facilitates secondary infections. As the secondary infections resulting from weakened immunity have a space for antibiotics, the scope of remedial measures is wide.
In effect, there is not a final solution in the tremendous world of pathology. But generation of vaccines to fight the epidemics as a pre-emptive measure has by far been effective in the past. The time span required for developing a vaccine has been impressively diminishing over the years. As the genetic sequence of the new virus is made available by China, a vaccine is expected to be developed within a month as labs are working on it world over.
Read the landscape report to get similar insights and a competitor study for patents related to Coronavirus. You can play around a categorization of major patents in the field by clicking the following link, coronavirus taxonomy.
The dilemma of where, when, and how much to invest in the innovation space is a critical factor...Know More
M&A is a strategic process, aimed at a mutually supportive and complementary association, resulting in a synergized end...Know More
Innovation reaches a dead-end if it cannot be monetized when the innovator fails to trace and reach out...Know More
Management of IP assets is costly and labor-intensive. Relecura offers classifier tools for categorizing and organizing data automatically...Know More
Relecura’s forte is its flexibility and adaptability to address specific problems and close-fitting solutions. The basic problem is that innovators are often not able to identify the industrial and commercial significance of their innovation as due diligence takes long days of analyses, necessitating a deviation from their regular and familiar activities. And it is a tedious iteration process. The latest custom AI capabilities help you assess the commercial value of innovation and technical due diligence can be automated to yield meaningful and immediate results. The repetitive tasks could be automated, and your time and energy could be devoted to strategic missions.
Management of large Innovation data is costly and labor intensive. Relecura offers AI-powered classification tools for categorizing and organizing data automatically and instantly. Automated Categorization against suitably chosen training documents keeps your innovation portfolio updated and lucidly classified, amenable to instant analyses.
Relecura offers fully automated custom AI solutions to track and explore developments in different technology areas. You can stay updated on the latest developments in different companies and technologies of your interest, which facilitates intelligent decision-making.
Competitive intelligence is a prerequisite for strategic decision making. Relecura provides tools to track the innovation and publication dynamics of your competitors, based on which you can prioritize your innovation initiatives and thus hone up your competitive edge.
Relecura uses white space analysis within its product platform known as the TechTracker, an AI-powered tool that provides insights on various technological trends and offers a peep into your competitor’s patent arsenal. Additionally, it helps you keep track of emerging organizations and technologies to help you manage your budgets and investments, optimally.
“Relecura helps us remain innovative by allowing us to see where the competition is playing through the landscaping tools. It lets us see where there are new opportunities and helps us focus in on those areas in an intelligent way.”
“Relecura helps us ride the crest of innovation wave keeping a competitive edge.” It helps us identify the white spaces and where the opportunities are.”
‘Our policy decisions regarding the focus areas of research and investment are being taken based on the insights offered by the custom AI tool, TechTracker, which offers a clear picture about the emerging technologies, companies, and the white spaces on the technology landscape of the key players. This helps us optimize resource utilization and maximize returns,’
‘The Classifier tool, introduced by Relecura, is indeed useful in managing and updating large datasets. After having subscribed to that AI-powered tool, in-house big data management and analyses have become easier and hassle-free.”
“Relecura platform is fueled by the latest technologies, and the tools that the platform hosts make our in-house innovation management smooth and accurate, in addition to being synchronized with the global technology frontline.”
Make faster, better technology decisions with Relecura
Our professional services offer training and support to minimise time-to-value on the Relecura platform and make more timely, confident IP decisions